MARKET

LXRX

LXRX

Lexicon PHARM
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.780
-0.170
-8.72%
Pre Market: 1.820 +0.04 +2.25% 08:59 04/02 EDT
OPEN
1.890
PREV CLOSE
1.950
HIGH
1.960
LOW
1.750
VOLUME
740.19K
TURNOVER
--
52 WEEK HIGH
7.27
52 WEEK LOW
1.125
MARKET CAP
190.41M
P/E (TTM)
1.720
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average LXRX stock price target is 5.10 with a high estimate of 10.00 and a low estimate of 2.300.

EPS

LXRX News

More
  • Edited Transcript of LXRX earnings conference call or presentation 12-Mar-20 12:00pm GMT
  • Thomson Reuters StreetEvents · 3d ago
  • Lexicon Pharmaceuticals Moving On From Diabetes And Pivoting Toward Clinical Candidates
  • Seeking Alpha - Article · 03/24 17:20
  • Mylan's COVID-19 Medicine, And Other News: The Good, Bad And Ugly Of Biopharma
  • Seeking Alpha - Article · 03/22 11:20
  • The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company
  • Benzinga · 03/20 12:44

Industry

Biotechnology & Medical Research
-4.52%
Pharmaceuticals & Medical Research
-2.91%

Hot Stocks

Symbol
Price
%Change

About LXRX

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development. XERMELO is an orally-delivered small molecule compound approved by the Food and Drug Administration (FDA) for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. It is developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for type 1 and type 2 diabetes mellitus. LX2761 is an orally-delivered small molecule compound that it is developing for the treatment of diabetes. LX9211 is an orally-delivered small molecule compound that the Company is developing for the treatment of neuropathic pain.
More

Webull offers kinds of Lexicon Pharmaceuticals, Inc. stock information, including NASDAQ:LXRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LXRX stock news, and many more online research tools to help you make informed decisions.